Literature DB >> 15265259

Impact of migraine on patients and their families: the Migraine And Zolmitriptan Evaluation (MAZE) survey--Phase III.

E A MacGregor1, J Brandes, A Eikermann, R Giammarco.   

Abstract

OBJECTIVE: To investigate the impact of migraine on migraineurs and their families and evaluate migraineurs' preference for different treatment formulations. This study also assessed the prevalence and impact of migraine with menstruation.
METHODS: Participants (n = 1028) from around the world (USA [39%], Canada [20%], Europe [37%] and other countries [4%]) completed an online questionnaire. Of these, 866 were migraineurs and 162 were non-migraineurs living with/related to migraineurs. Migraineurs were identified based on responses to a modified Kiel questionnaire and/or diagnosis of migraine by a doctor. Disability was quantified using the Migraine Disability Assessment Scale (MIDAS).
RESULTS: Migraineurs missed more days from family/leisure activities than from work/school (mean 4.2 vs 2.4 days) in the previous 3 months. On an additional 6.2 days within the 3-month period, productivity at work/school was reduced by at least half. Inability and reduced ability (by at least half) to perform household work were reported on 6.0 and 6.5 days, respectively. Of the women surveyed, 51% identified menstruation as a trigger for attacks and 6% reported attacks solely with menstruation (i. e. attacks occurred during menstruation on at least 9 out of 10 occasions), the latter associated with a higher pain score than other attacks. Living with or being related to a migraineur decreased nonmigraineurs' ability to participate in home/family life (moderate/great impact 49%) and social/leisure activities (moderate/great impact 47%). In a tradeoff analysis, 60% of treatment choice was driven by formulation type and 40% was driven by speed of onset. As migraine disability increased, speed of onset became more important.
CONCLUSIONS: This study confirms the significant burden of migraine on patients and families/cohabitants, highlighting not only reduced productivity and absences from work/school, but also time missed from family/social occasions. Many women identify menstruation to be associated with more painful attacks. Overall, in terms of treatment choice, formulation type was a more important driver than speed of onset; however, as migrainerelated disability escalates, speed of onset becomes more important. To optimise migraine management, treatment choice should be based on individual patients' needs and preferences.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15265259     DOI: 10.1185/030079904125004178

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  24 in total

1.  Clinical trials report: sumatriptan-naproxen combination for symptomatic treatment of comorbid dysmenorrhea and migraine.

Authors:  E Anne MacGregor
Journal:  Curr Pain Headache Rep       Date:  2010-10

2.  Menstrual migraine: therapeutic approaches.

Authors:  E Anne Macgregor
Journal:  Ther Adv Neurol Disord       Date:  2009-09       Impact factor: 6.570

3.  Effectiveness and satisfaction with zolmitriptan 5 mg nasal spray for treatment of migraine in real-life practice: results of a postmarketing surveillance study.

Authors:  Hans-Christoph Diener; Stefan Evers
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

Review 4.  The Impact of Parental Migraine on Children.

Authors:  Maya Marzouk; Elizabeth K Seng
Journal:  Curr Pain Headache Rep       Date:  2021-01-06

5.  The Impact of Post-Traumatic Stress Disorder on the Burden of Migraine: Results From the National Comorbidity Survey-Replication.

Authors:  Aruna S Rao; Ann I Scher; Rebeca V A Vieira; Kathleen R Merikangas; Andrea L Metti; B Lee Peterlin
Journal:  Headache       Date:  2015-10-16       Impact factor: 5.887

6.  Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine.

Authors:  Michael Tuchman; Angela Hee; Ugochi Emeribe; Stephen Silberstein
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 7.  Non-oral formulations of triptans and their use in acute migraine.

Authors:  Carl G H Dahlöf
Journal:  Curr Pain Headache Rep       Date:  2005-06

Review 8.  Prevention and treatment of menstrual migraine.

Authors:  E Anne MacGregor
Journal:  Drugs       Date:  2010-10-01       Impact factor: 9.546

9.  Oral zolmitriptan in the short-term prevention of menstrual migraine: a randomized, placebo-controlled study.

Authors:  Michael M Tuchman; Angela Hee; Ugochi Emeribe; Stephen Silberstein
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

10.  Quality of life, eating and mood disorders in menstrual migraine: a case-control study.

Authors:  Marianna Nicodemo; Luca Vignatelli; Daniela Grimaldi; Elisa Sancisi; Jean Elia Fares; Stefano Zanigni; Giulia Pierangeli; Pietro Cortelli; Pasquale Montagna; Sabina Cevoli
Journal:  Neurol Sci       Date:  2008-05       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.